VJHemOnc Podcast The AML Sessions: Immunotherapy
Oct 8, 2020
Leading expert in immuno-oncology, Marion Subklewe, leads a panel discussion on checkpoint inhibitors, anti-CD47 therapy, BiTEs, and CAR T-cell approaches in AML. Topics covered include progress and challenges of immunotherapy, anti CD47 drug responses, challenges of using bi-specifics, and understanding the challenges and potential of immunotherapy.
Chapters
Transcript
Episode notes
1 2 3 4 5 6
Introduction
00:00 • 2min
Current Status and Future Direction of Immunotherapy in AML
02:05 • 8min
Checkpoint Inhibitors and CD47 Targeting in High-Risk MDS
09:43 • 8min
Discussion on an anti CD47 drug and its lack of responses, potential differences in agents, and the need for further data and trials
17:41 • 3min
Challenges and Progress in Using Bi-Specifics for AML Treatment
20:43 • 12min
Understanding the Challenges and Potential of Immunotherapy
32:18 • 3min